ARPI
ARPI 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Prostate Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
10 项
已进入 III/IV 期
27 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Novartis Pharmaceuticals
- University of Utah
- ORIC Pharmaceuticals
- European Organisation for Research and Treatment of Cancer - EORTC
- Cedars-Sinai Medical Center
- Hoffmann-La Roche
- AstraZeneca
- University College, London
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Puerto Rico、澳大利亚、西班牙、英国、丹麦、法国、加拿大、德国、意大利、日本、South Korea
正在招募患者的 ARPI 研究
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
II 期招募中美国NCT07216248A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
III 期招募中美国Puerto RicoNCT07723248A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
不适用招募中美国NCT07677267Study of ORIC-944 in Patients With Metastatic Prostate Cancer
I 期招募中美国澳大利亚西班牙英国NCT05413421Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
III 期招募中丹麦法国西班牙NCT05974774High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
II 期招募中美国NCT07223385A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
I 期招募中美国澳大利亚加拿大德国NCT07570979A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
II 期招募中美国澳大利亚Brazil加拿大NCT07287150Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
III 期招募中美国奥地利Brazil加拿大NCT07711002Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
III 期招募中英国NCT07751133Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
I 期 / II 期招募中澳大利亚NCT05720130A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
I 期 / II 期招募中美国澳大利亚法国德国NCT07226986Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
III 期招募中美国加拿大MexicoUruguayNCT06592924Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
III 期招募中美国澳大利亚Brazil中国NCT06855277Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
IV 期招募中加拿大NCT07252726Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
不适用招募中瑞典NCT04983095A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
III 期招募中英国NCT06320067Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
III 期招募中荷兰NCT07260435Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
不适用招募中中国NCT07290270An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
I 期 / II 期招募中美国澳大利亚加拿大中国NCT07206056A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
III 期招募中澳大利亚加拿大日本South KoreaNCT07802704Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
不适用招募中澳大利亚NCT07552922Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
II 期招募中美国NCT07466498Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
II 期招募中法国西班牙NCT06582628
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。